Niagen Bioscience, Inc. (formerly ChromaDex Corp.) — Cyborg Score 6/10

Solid
NAD+ and healthy aging supplements

Strategic Profile

The company operates through three segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services, with the majority of revenue from Consumer Products. The company has partnered with multiple research institutions including the National Institutes of Health and Northwestern University Feinberg School of Medicine to study nicotinamide riboside benefits.

Cyborg Score Rationale

Q1 2026 showed total net sales of $31.5 million with Tru Niagen contributing $22.4 million, a 3% increase year-over-year. The company maintains strong gross margins and a differentiated product, but faces challenges including supply chain risks and a relatively small market cap for a public biotech company.

Top Insights

  • Tru Niagen generated $22.4 million of $31.5 million in Q1 2026 revenue, representing 71% of sales and the core growth engine
  • Company rebranded to Niagen Bioscience and changed ticker symbol to NAGE in March 2025, signaling strategic shift toward brand-focused identity
  • Strategic partnerships with elite research institutions (NIH, Northwestern) provide scientific credibility and product validation in competitive aging supplement market
  • Q1 2026 organic revenue growth of 5% (excluding divested Analytical Reference Standards segment) shows underlying business momentum

Named Competitors

  • Basis — NAD+ booster supplement competitor in healthy aging
  • Tru Niagen — Flagship NAD+ precursor supplement using patented nicotinamide riboside (NR)
  • Nád — NAD+ supplement offering NR and NMN variants for healthy aging
  • NAD+ Pro — Premium NAD+ precursor supplement targeting aging consumers

Recent Developments

  • (March 2025) Rebranded from ChromaDex Corp. to Niagen Bioscience and changed NASDAQ ticker from CDXC to NAGE
  • (Q1 2026) Reported total net sales of $31.5 million with 3% year-over-year growth; Tru Niagen sales reached $22.4 million
  • (May 2026) Senior leadership participated in 31st Annual Sohn Investment Conference Emerging Company Pavilion

Open the full interactive Niagen Bioscience, Inc. (formerly ChromaDex Corp.) report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →